CytoDyn Announces Leadership Changes to Align with Expanded Focus of PRO 140 to Cancer and Immunological Disorders Jul 12, 2018 4:15pm EDT
CytoDyn to Expand Strategic Focus with PRO 140 to Cancer and Immunologic Disorders Jul 12, 2018 4:05pm EDT
New Research Supports Potential for CytoDyn’s PRO 140 to Inhibit Breast Cancer Metastasis Jun 26, 2018 6:00am EDT
CytoDyn Announces Productive Pre-BLA Meeting with FDA for PRO 140 Combination Therapy Jun 22, 2018 6:00am EDT
CytoDyn ASM Poster Presentation June 9, 2018, at ASM Microbe 2018, Atlanta, GA Jun 11, 2018 6:00am EDT
Results from CytoDyn’s Pivotal PRO 140 Combination Therapy Trial in HIV to be Presented at ASM Microbe 2018 on June 9 Jun 04, 2018 6:00am EDT
Results of CytoDyn’s PRO 140 CD01 Trial and Extension Study Published in HIV Clinical Trials May 24, 2018 5:00pm EDT
CytoDyn to Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM Microbe 2018 Apr 11, 2018 4:30pm EDT
CytoDyn Forms Scientific Advisory Board to Advance PRO 140 Development in Immunological Disorders Mar 29, 2018 6:00am EDT
